Allogene Therapeutics, Inc.
Status: Publicly traded
Direct answer
Allogene Therapeutics, Inc. is publicly traded on NASDAQ under the ticker ALLO.
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market...
Can you invest in Allogene Therapeutics, Inc.?
Yes. Allogene Therapeutics, Inc. is publicly traded on NASDAQ under the ticker ALLO.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Allogene Therapeutics, Inc.
Detailed equity research is provided by MarketSnap.